8-K: Cartesian Therapeutics Announces Positive 12-Month Data from Phase 2b Myasthenia Gravis Trial

Cartesian Therapeutics reports sustained benefits and a favorable safety profile for Descartes-08 in myasthenia gravis patients after a single six-week course of treatment.

Summary

• Cartesian Therapeutics announced positive 12-month efficacy and safety data from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis (MG).
• Participants treated with a single six-week course of Descartes-08 experienced sustained symptom improvement at the 12-month assessment.
• The primary efficacy dataset included 12 out of 15 participants who completed their Month 12 follow-up assessments.
• Participants showed an average MG-ADL reduction of 5.5 points at Month 4 and 4.8 points at Month 12.
• Participants showed an average Quantitative Myasthenia Gravis Score (QMG) reduction of 4.8 points at Month 4, deepening to 6.0 points at Month 12.
• 33% of participants achieved minimum symptom expression (MSE) at Month 6, maintaining it through Month 12.
• 83% of evaluable participants maintained a clinically meaningful response through Month 12, defined as a reduction in MG-ADL score of at least 2 points.
• Participants without prior biologic therapies showed an average MG-ADL reduction of 6.6 points at Month 4 and 7.1 points at Month 12.
• Participants without prior biologic therapies showed an average QMG reduction of 5.9 points at Month 4, deepening to 9.4 points at Month 12.
• 57% of participants without prior biologic therapies achieved MSE at Month 6, maintaining it through Month 12.
• 100% of participants without prior biologic therapies maintained at least a clinically meaningful response through Month 12.
• Descartes-08 was well-tolerated, with no new adverse events reported in the 12-month follow-up data.
• There were no cases of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS).
• Treatment with Descartes-08 did not lead to a decrease in vaccine titers or increased rates of infection or hypogammaglobulinemia.
• The Phase 3 AURORA trial is on track to dose the first patient in 2Q25.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial data with sustained benefits and a favorable safety profile, indicating a promising outlook for Descartes-08 and the company. The Phase 3 trial is on track, and the company has received key designations from the FDA.

Positives

• Sustained symptom improvement in myasthenia gravis patients after a single six-week course of Descartes-08.
• Deep responses observed through Month 12, with an average MG-ADL reduction of 4.8 points.
• Clinically meaningful response maintained by 83% of evaluable participants through Month 12.
• Participants without prior biologic therapies exhibited deepening responses, with an average MG-ADL reduction of 7.1 points at Month 12.
• Well-tolerated safety profile supports outpatient administration without lymphodepleting chemotherapy.
• No new adverse events reported in the 12-month follow-up data.
• Phase 3 AURORA trial on track to dose first patient in 2Q25.
• Descartes-08 has been granted Regenerative Medicine Advanced Therapy (RMAT) Designation and Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of MG.
• Cartesian received written agreement from the FDA under the Special Protocol Assessment (SPA) process indicating the overall design of the planned Phase 3 AURORA trial of Descartes-08 is acceptable to support a future Biologics License Application in MG, subject to the ultimate outcome of the trial.

Negatives

• Three participants were lost to follow-up after their Month 3 assessments, potentially affecting the overall data interpretation.
• Infusion-related reactions such as fever, chills, headache, and nausea were common side effects through the Month 3 primary endpoint.

Risks

• The uncertainties inherent in the initiation, completion and cost of clinical trials including proof of concept trials, including uncertain outcomes.
• The availability and timing of data from ongoing and future clinical trials and the results of such trials.
• Whether preliminary results from a particular clinical trial will be predictive of the final results of that trial.
• Potential delays in enrollment of patients.
• Undesirable side effects of the Company's product candidates.
• The Company's reliance on third parties to conduct its clinical trials.
• The Company's inability to maintain its existing or future collaborations, licenses or contractual relationships.
• The Company's inability to protect its proprietary technology and intellectual property.
• Potential delays in regulatory approvals.
• The availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements.
• The Company's recurring losses from operations and negative cash flows.
• Substantial fluctuation in the price of the Company's common stock.
• Risks related to geopolitical conflicts and pandemics.

Future Outlook

The company anticipates commencing the Phase 3 AURORA trial of Descartes-08 in MG in the second quarter of 2025 and continues to develop Descartes-08 for other autoimmune indications.

Management Comments

• 'This impressive data highlights the potential of Descartes-08 to serve as an important therapeutic option to deliver deep and sustained reductions in MG-ADL for patients with myasthenia gravis', said Tuan Vu, M.D., Professor of Neurology at the University of South Florida Morsani College of Medicine, Division Director for Neuromuscular Medicine and EMG and investigator in the Phase 2b trial.
• The remarkable results presented today underscore the potential of utilizing our cell therapy to deliver deep and durable responses in MG patients one year after receiving a single course of therapy in a convenient outpatient setting with no preconditioning chemotherapy, said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian.
• We look forward to dosing the first patient in our Phase 3 AURORA trial in the second quarter of this year, said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian.

Industry Context

The announcement positions Cartesian Therapeutics as a potential leader in cell therapy for autoimmune diseases, particularly myasthenia gravis, offering a treatment option that could provide sustained benefits with a convenient outpatient administration and without the need for preconditioning chemotherapy, differentiating it from some existing therapies.

Comparison to Industry Standards

• The reported MG-ADL reduction of 4.8 points at Month 12 is a clinically meaningful improvement and compares favorably to results seen with other approved therapies for myasthenia gravis, such as eculizumab and ravulizumab, which target the complement pathway.
• Unlike traditional CAR-T therapies that require lymphodepleting chemotherapy, Descartes-08 is designed to be administered without preconditioning, potentially offering a safer and more convenient treatment option.
• The sustained responses observed in patients without prior exposure to biologic therapies suggest that Descartes-08 may be particularly effective in this subgroup, potentially positioning it as a first-line biologic therapy for myasthenia gravis.
• Companies like Argenx (Vyvgart) and UCB (Rystiggo) have established biologics in the MG space, but Descartes-08's cell therapy approach could offer a more durable response after a single course of treatment.

Stakeholder Impact

• Shareholders: Positive clinical trial data may increase investor confidence and potentially lead to a higher stock price.
• Patients: Descartes-08 offers a potential new treatment option for myasthenia gravis with sustained benefits and a favorable safety profile.
• Employees: Successful clinical trials and regulatory approvals could lead to company growth and job security.
• Suppliers: Increased demand for manufacturing and clinical trial services.
• Creditors: Improved financial outlook for the company.

Next Steps

• Dosing the first patient in the Phase 3 AURORA trial in the second quarter of 2025.
• Continuing the open-label Phase 2 trial in Systemic Lupus Erythematosus (SLE) with data readout expected in 2H25.
• Initiating the Pediatric basket trial expected in 2H25.
• Continuing dosing in first-in-human Phase 1 dose escalation trial of DESCARTES-15.

Key Dates

Keywords

Descartes-08, Myasthenia Gravis, Cell Therapy, Autoimmune Disease, Clinical Trial, Efficacy, Safety, Phase 2b, Phase 3, AURORA, RMAT Designation, Orphan Drug Designation